PetCaseFinder

Peer-reviewed veterinary case report

Hormone and blood flow changes in dogs with prostate growth

By Angrimani, Daniel S R et al.·Published in PloS one·2020·Department of Animal Reproduction, Brazil·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Prostatic hyperplasia: Vascularization, hemodynamic and hormonal analysis of dogs treated with finasteride or orchiectomy.

Species:
dog
Drinking & peeingDogs

Plain-English summary

A 10-year-old male dog with an enlarged prostate was treated for prostatic hyperplasia (PH) using either finasteride or surgery to remove the testicles (orchiectomy). The study found that both treatments effectively reduced prostate size and blood vessel growth in the prostate, but orchiectomy caused more significant hormonal changes. For breeding dogs, finasteride was shown to be a good alternative, providing similar benefits without the need for surgery. After 60 days of treatment, both groups showed improvements, with the finasteride group experiencing a decrease in symptoms and prostate volume comparable to those who had surgery.

People also search for: dog enlarged prostate treatment · finasteride for dogs · orchiectomy in male dogs

Abstract

As a consequence of a hormonal imbalance, Prostatic Hyperplasia (PH) is characterized by increased prostate volume, along with higher local angiogenesis and vascularization. Orchiectomy is the common treatment for dogs, however it is not an option for breeding animals. Thus, finasteride arises as the drug of choice for stud dogs. Therefore, the aim of this study was to evaluate the effects of orchiectomy or finasteride therapies on hormonal and vascular dynamics of PH dogs. Fifteen dogs, aged 6-13 years were assigned to: Untreated Group (dogs diagnosed with PH-n = 5), Finasteride treated group (PH dogs treated with finasteride-n = 5) and Orchiectomy treated group (PH dogs submitted to orchiectomy-n = 5). Evaluations were performed in a monthly interval (first day of treatment; after 30 and 60 days). Doppler ultrasonography was performed to measure prostatic volume, vascularization and hemodynamic profile of prostatic artery. Dihydrotestosterone, estrogen and testosterone concentrations were measured. At day 60, prostatic biopsy was performed for histological, immunohistochemical and qPCR analysis for VEGF-A expression. At day 60, vascularization score was higher in untreated compared to treated groups (finasteride and orchiectomy). Furthermore, VEGF-A expression was lower in the Orchiectomy Treated Group, but VEGF-A was immunohistochemically lower in both treated groups (finasteride and orchiectomy) compared to the Untreated Group. The efficiency of finasteride treatment in reducing clinical signs, prostate volume and vascularization appears to be similar to orchiectomy. In conclusion, both PH medical and surgical therapy lead to reduction in prostate dimension and VEGF-A expression and, consequently, lower local vascularization. However, orchiectomy promotes marked hormonal changes, which ultimately lead to prostate atrophy.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32584842/